Dewpoint Therapeutics and ConcertAI Announce the First Phase …
16 hours ago · Supporting Dewpoint’s novel condensate modulating approach to drug previously ‘undruggable’ therapeutic targets, guided by ConcertAI’s Clinico-Genomic Solutions Boston, MA and Cambridge, MA, December 12, 2024 – Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around ...
Dewpoint Therapeutics and ConcertAI Announce the First Phase …
4 hours ago · Dewpoint’s pipeline consists of wholly owned and partnered programs. To date, the company has raised $287M through series C and is planning 2 INDs in 2025. The total value of partnered programs ...
News - Dewpoint Therapeutics
Oct 28, 2024 · A single source to discover Dewpoint's news updates, press releases and publications.
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma …
Dec 4, 2024 · BOSTON, Massachusetts, December 4, 2024 – Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small ...
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma …
BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced today that it ...
Dewpoint Therapeutics lays off staff after losing partnerships
Jan 16, 2024 · Dewpoint, one of a handful of startups going after biomolecular condensates, said it cut 15% of employees and lost two pharma partnerships.
Dewpoint lays off 20, says cuts not tied to partnership closures
Jan 17, 2024 · Dewpoint Therapeutics is slimming down its team as it focuses on bringing two projects into the clinic. The Boston-based biotech, which is focused on a unit of cells known as biomolecular...
Dewpoint Therapeutics and ConcertAI Announce the First
4 hours ago · Dewpoint’s proprietary AI/ML-powered state-of-the-art platform underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary ...
Mitsubishi teams up with Dewpoint in $480m ALS deal
Dec 5, 2024 · Dewpoint’s preclinical-stage condensate modulator (c-mod) is designed to stop the clumping of TDP-43 and restore nerve cells to a healthy state. The compound has shown signs of tackling ALS in animal models, and similar drugs could be used to treat other conditions linked to biomolecular condensates including cancer, diabetes, and ...
Dewpoint, Mitsubishi partner on ALS drug in deal worth up to …
Dec 4, 2024 · Dewpoint Therapeutics, a young biotechnology company, could receive nearly half a billion dollars if all goes to plan in a new partnership focused on its experimental medicine for ALS.